The efficacy of ampicillin and Lactobacillus casei rhamnosus in the active management of preterm premature rupture of membranes remote from term

Background We aimed to investigate the treatment efficacy of ampicillin prophylaxis accompanied by Lactobacillus casei rhamnosus over the latency period following preterm premature rupture of membranes (PPROM). Methods Records of 40 patients who presented with PPROM between 230/7–316/7 weeks were analyzed retrospectively. Patients were divided into two groups: group 1 (n=20), treated with ampicillin; and group 2 (n=20), treated with ampicillin plus L. casei rhamnosus. Clinical and laboratory parameters were compared. Delta (Δ) values of each laboratory parameter were calculated by subtracting the value at delivery from the values at admission to the clinic. Results Gestational weeks at delivery (28.1±0.3 weeks versus 31.5±0.4 weeks), latency periods (12.3±1.5 days versus 41.4±4.4 days), 5-minute APGAR scores (6.8±0.1 versus 7.8±0.1), and birth weights (1,320±98 g versus 1,947±128 g) were significantly higher in group 2. White blood cell (WBC) (12,820±353/mm3 versus 11,107±298/mm3), and neutrophil counts (10.7±0.5×103/L versus 8.2±0.5×103/L) were significantly lower in group 2 at delivery. The ΔWBC (2,295±74/mm3 versus −798±−406/mm3), ΔC-reactive protein (5±0.04 mg/L versus 1.6±0.2 mg/L), and Δneutrophil (3±0.2×103/L versus 0.2±−0.1×103/L) were significantly lower in group 2. Conclusion It seems that addition of L. casei rhamnosus to ampicillin prolongs the latency period in patients with PPROM remote from term.

[1]  T. Garite,et al.  17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial , 2011, BMC Research Notes.

[2]  M. Hod,et al.  Expectant management of preterm premature rupture of membranes: is it all about gestational age? , 2011, American journal of obstetrics and gynecology.

[3]  B. Kramer,et al.  Histologic chorioamnionitis, fetal involvement, and antenatal steroids: effects on neonatal outcome in preterm infants. , 2009, American journal of obstetrics and gynecology.

[4]  R. Écochard,et al.  Neonatal outcomes after elective delivery management of preterm premature rupture of the membranes before 34 weeks' gestation (DOMINOS study). , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[5]  M. Chikindas,et al.  Safety Study of an Antimicrobial Peptide Lactocin 160, Produced by the Vaginal Lactobacillus rhamnosus , 2007, Infectious diseases in obstetrics and gynecology.

[6]  G. Reid,et al.  Effect of Lactobacillus challenge on Gardnerella vaginalis biofilms. , 2007, Colloids and surfaces. B, Biointerfaces.

[7]  ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. , 2007, Obstetrics and gynecology.

[8]  G. Reid,et al.  Probiotics: 100 years (1907-2007) after Elie Metchnikoff's Observations , 2007 .

[9]  D. Brassart,et al.  Lactobacillus strains isolated from the vaginal microbiota of healthy women inhibit Prevotella bivia and Gardnerella vaginalis in coculture and cell culture. , 2006, FEMS immunology and medical microbiology.

[10]  B. Mercer.  Preterm premature rupture of the membranes: current approaches to evaluation and management. , 2005, Obstetrics and gynecology clinics of North America.

[11]  M. Chikindas,et al.  Mode of action of lactocin 160, a bacteriocin from vaginal Lactobacillus rhamnosus. , 2005, Infectious diseases in obstetrics and gynecology.

[12]  M. Sugimoto,et al.  Clinical study of the effectiveness of imipenem/cilastatin sodium as the antibiotics of first choice in the expectant management of patients with preterm premature rupture of membranes , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[13]  S. Gopalani,et al.  Contemporary management of preterm premature rupture of membranes: determinants of latency and neonatal outcome. , 2004, American journal of perinatology.

[14]  B. Mercer,et al.  Perinatal intervention and neonatal outcomes near the limit of viability. , 2003, American journal of obstetrics and gynecology.

[15]  J. Yeast.  Preterm premature rupture of the membranes before viability. , 2001, Clinics in perinatology.

[16]  S. Faro,et al.  Antimicrobial Protein Produced by Vaginal Lactobacillus acidophilus that inhibits Gardnerella vaginalis , 2001, Infectious diseases in obstetrics and gynecology.

[17]  J. Suárez,et al.  Adherence of Human Vaginal Lactobacilli to Vaginal Epithelial Cells and Interaction with Uropathogens , 1998, Infection and Immunity.

[18]  G. Thurnau,et al.  Antibiotic Therapy for Reduction of Infant Morbidity After Preterm Premature Rupture of the Membranes: A Randomized Controlled Trial , 1997 .

[19]  G. Thurnau,et al.  Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 1997, JAMA.

[20]  S. Kenyon,et al.  Preterm premature rupture of membranes. , 2012, Archivos argentinos de pediatria.

[21]  R. Romero,et al.  A review of premature birth and subclinical infection. , 1992, American journal of obstetrics and gynecology.